783 related articles for article (PubMed ID: 29356032)
1. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.
Caussy C; Reeder SB; Sirlin CB; Loomba R
Hepatology; 2018 Aug; 68(2):763-772. PubMed ID: 29356032
[TBL] [Abstract][Full Text] [Related]
2. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis.
Andersson A; Kelly M; Imajo K; Nakajima A; Fallowfield JA; Hirschfield G; Pavlides M; Sanyal AJ; Noureddin M; Banerjee R; Dennis A; Harrison S
Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2451-2461.e3. PubMed ID: 34626833
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease.
Imajo K; Honda Y; Yoneda M; Saito S; Nakajima A
J Med Ultrason (2001); 2020 Oct; 47(4):535-548. PubMed ID: 33108553
[TBL] [Abstract][Full Text] [Related]
4. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.
Alsaqal S; Hockings P; Ahlström H; Gummesson A; Hedström A; Hulthe J; Johansson L; Niessen HG; Schoelch C; Schultheis C; Vessby J; Wanders A; Rorsman F; Ebeling Barbier C
J Magn Reson Imaging; 2022 Aug; 56(2):368-379. PubMed ID: 34953171
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Quantitative Imaging Biomarkers for Early-phase Clinical Trials of Steatohepatitis in Adolescents.
Goyal NP; Sawh MC; Ugalde-Nicalo P; Angeles JE; Proudfoot JA; Newton KP; Middleton MS; Sirlin CB; Schwimmer JB
J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):99-105. PubMed ID: 31633654
[TBL] [Abstract][Full Text] [Related]
6. Imaging biomarkers of NAFLD, NASH, and fibrosis.
Ajmera V; Loomba R
Mol Metab; 2021 Aug; 50():101167. PubMed ID: 33460786
[TBL] [Abstract][Full Text] [Related]
7. Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis.
Dennis A; Kelly MD; Fernandes C; Mouchti S; Fallowfield JA; Hirschfield G; Pavlides M; Harrison S; Chakravarthy MV; Banerjee R; Sanyal A
Front Endocrinol (Lausanne); 2020; 11():575843. PubMed ID: 33584535
[TBL] [Abstract][Full Text] [Related]
8. Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
Stine JG; Munaganuru N; Barnard A; Wang JL; Kaulback K; Argo CK; Singh S; Fowler KJ; Sirlin CB; Loomba R
Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2274-2283.e5. PubMed ID: 32882428
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease.
Schaapman JJ; Tushuizen ME; Coenraad MJ; Lamb HJ
J Magn Reson Imaging; 2021 Jun; 53(6):1623-1631. PubMed ID: 32822095
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Kogachi S; Noureddin M
Clin Ther; 2021 Mar; 43(3):455-472. PubMed ID: 33581876
[TBL] [Abstract][Full Text] [Related]
12. Liver fat quantification: where do we stand?
Starekova J; Reeder SB
Abdom Radiol (NY); 2020 Nov; 45(11):3386-3399. PubMed ID: 33025153
[TBL] [Abstract][Full Text] [Related]
13. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.
Loomba R; Neuschwander-Tetri BA; Sanyal A; Chalasani N; Diehl AM; Terrault N; Kowdley K; Dasarathy S; Kleiner D; Behling C; Lavine J; Van Natta M; Middleton M; Tonascia J; Sirlin C;
Hepatology; 2020 Oct; 72(4):1219-1229. PubMed ID: 31965579
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease.
Lee SJ; Kim SU
Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):523-530. PubMed ID: 31018719
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive Diagnosis of NAFLD and NASH.
Piazzolla VA; Mangia A
Cells; 2020 Apr; 9(4):. PubMed ID: 32316690
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.
Tamaki N; Ajmera V; Loomba R
Nat Rev Endocrinol; 2022 Jan; 18(1):55-66. PubMed ID: 34815553
[TBL] [Abstract][Full Text] [Related]
17. Automated Analysis of Multiparametric Magnetic Resonance Imaging/Magnetic Resonance Elastography Exams for Prediction of Nonalcoholic Steatohepatitis.
Dzyubak B; Li J; Chen J; Mara KC; Therneau TM; Venkatesh SK; Ehman RL; Allen AM; Yin M
J Magn Reson Imaging; 2021 Jul; 54(1):122-131. PubMed ID: 33586159
[TBL] [Abstract][Full Text] [Related]
18. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol.
Pavlides M; Mózes FE; Akhtar S; Wonders K; Cobbold J; Tunnicliffe EM; Allison M; Godfrey EM; Aithal GP; Francis S; Romero-Gomez M; Castell J; Fernandez-Lizaranzu I; Aller R; González RS; Agustin S; Pericàs JM; Boursier J; Aube C; Ratziu V; Wagner M; Petta S; Antonucci M; Bugianesi E; Faletti R; Miele L; Geier A; Schattenberg JM; Tilman E; Ekstedt M; Lundberg P; Berzigotti A; Huber AT; Papatheodoridis G; Yki-Järvinen H; Porthan K; Schneider MJ; Hockings P; Shumbayawonda E; Banerjee R; Pepin K; Kalutkiewicz M; Ehman RL; Trylesinksi A; Coxson HO; ; Martic M; Yunis C; Tuthill T; Bossuyt PM; Anstee QM; Neubauer S; Harrison S
Contemp Clin Trials; 2023 Nov; 134():107352. PubMed ID: 37802221
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Steatohepatitis: A Review.
Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
[TBL] [Abstract][Full Text] [Related]
20. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
